Children's Mercy Kansas City

SHARE @ Children's Mercy
Clinical Practice Guidelines

Quality Improvement and Clinical Safety

7-2021

Initial Diabetic Ketoacidosis
Children's Mercy Kansas City

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/clinical_guidelines
Part of the Pediatrics Commons

These guidelines do not establish a standard of care to be followed in every case. It is
recognized that each case is different and those individuals involved in providing health care are
expected to use their judgment in determining what is in the best interests of the patient based
on the circumstances existing at the time. It is impossible to anticipate all possible situations
that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Initial April 29, 2013; Revisions: 4/13; 1/14; 9/14; 12/14; 12/15,
12/16;11/19; 07/21

Children’s Mercy Hospitals and Clinics
Evidence Based Practice
Algorithm:

Diabetic Ketoacidosis Clinical Practice Guideline with
Hyperglycemic Hyperosmolar Syndrome Care Process Model

The Office of Evidence Based Practice, 2021
Service & Performance Excellence

1

Initial April 29, 2013; Revisions: 4/13; 1/14; 9/14; 12/14; 12/15,
12/16;11/19; 07/21
Insulin Drip Algorithm

The Office of Evidence Based Practice, 2021
Service & Performance Excellence

2

Initial April 29, 2013; Revisions: 4/13; 1/14; 9/14; 12/14; 12/15,
12/16;11/19; 07/21
Epidemiology:
In most western countries, type 1 diabetes accounts for over 90% of childhood and adolescent diabetes,. Type 2
diabetes is becoming more common in adolescents, particularly in the peri-pubertal period, and accounts for a
significant proportion of youth onset diabetes in certain at risk populations (International Diabetes Federation,
2010).
Type 1 diabetes incidence varies greatly between different countries, within countries, and between different
ethnic populations. Annual incidence rate for childhood type 1 diabetes in the United States is 1 per 500-600
with the T1D incidence doubling every 20 years (Rogers, Kim, Banerjee & Lee, 2017). There has been a welldocumented rise in the incidence within the United States, with a disproportionately greater increase in those
under the age of 5 years. A seasonal variation in the presentation of new cases is well described, with the peak
being in the winter months (International Diabetes Federation, 2010).
Susceptibility to autoimmune type 1 diabetes is associated with multiple genetic loci. HLA genes having the
strongest known association and account for approximately 40% of familial clustering of type 1 diabetes.
Linkage to specific combinations of alleles at the DRB1, DQA1 and DQB1 loci, with both susceptible or protective
haplotypes (International Diabetes Federation, 2010).
The environmental triggers (chemical and/or viral) which initiate pancreatic beta cell destruction remain largely
unknown, but the process usually begins months to years before the manifestation of clinical symptoms.
Enterovirus infection has been associated with development of diabetes associated autoantibodies in some
populations and enteroviruses have been detected in the islets of individuals with diabetes (International Diabetes
Federation, 2010).
Despite familial aggregation, which accounts for approximately 10% of cases of type 1 diabetes, there is no
recognizable Mendelian pattern of inheritance. The concordance rates in the identical twin of a patient with type 1
diabetes is about 36%; for a sibling the risk is approximately 4% by age 20 years and 9.6% by age 60 years;
compared with 0.5 % for the general population. Type 1 diabetes is 2-3 times more common in the offspring of
fathers with diabetes (3.6–8.5%) compared with mothers with diabetes (1.3–3.6%) (International Diabetes
Federation, 2010).
Objective of Guideline: The objective of this guideline, besides standardizing care and the benefits associated
with care standardization, is to correct dehydration and acidosis, reverse ketosis, restore blood glucose to near
normal, avoid complications of therapy (including cerebral edema), and identify and treat any precipitating
event(s) to prevent future DKA.
Target Users: Physicians, nurse practitioners and staff nurses caring for children, with DKA, in Emergency
Departments, outpatient settings and inpatient settings. (Note: Endocrine Service is available for consultation.)
Guideline Inclusion Criteria: Patient has known or presumed diabetes mellitus (here to referred to as
“diabetes”) a CO2 <16 mmol/L.
Guideline Exclusion Criteria: Hyperglycemia without acidosis.
Clinical Questions Answered by Guideline:
1. In the pediatric patient presenting with DKA which route (intravenous or subcutaneous) of insulin
therapy is most efficacious in resolving DKA?
Differential Diagnosis: Three key features of diabetic acidosis are hyperglycemia, ketosis, and dehydration. The
conditions that cause these metabolic abnormalities overlap. The primary differential diagnosis for hyperglycemia
is hyperosmolar hyperglycemic state.
Abdominal pain may be a symptom of ketoacidosis or part of the inciting cause of DKA, such as appendicitis or
cholecystitis. If surgery is necessary, the timing needs to be individualized for each patient with input from a
surgical consultant (Trachtenbarg, 2005). No patient with hyperglycemia should go to the OR prior to Endocrine
consultation.
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Practice Recommendations: are based on the degree of acidosis defined as:

•
•
•

Severe: bicarbonate < 5mmol/L, venous pH < 7.1

•
•
•
•
•
•
•

Family history of diabetes

•
•

Steroid use

Moderate: bicarbonate 5-10mmol/L, venous pH < 7.2

Mild: bicarbonate 11-15mmol/L, venous pH < 7.3
Diagnostic evaluation:
1. History:

2.

Polyuria, polydipsia, polyphagia
Weight loss
Abdominal pain, nausea, vomiting
Mental status
Concurrent illness or infections
Inadequate insulin therapy in a known diabetic such as non-adherence or inappropriate dosing or
interruption of insulin delivery from insulin pump

Age 3 years or less (increased risk for cerebral edema)
Physical Exam (PE)/Monitoring: The degree of acidosis (mild, moderate, severe) is an
important marker for determining the severity of DKA and is a risk factor for cerebral edema.
PE/monitoring include:

•
•
•

Assess dehydration - in DKA patients’ clinical assessment of dehydration can be imprecise. May
assume 5-10% dehydration in moderate to severe DKA.
Assess level of consciousness

Assess for Kussmaul respirations – deep labored breathing
Mild DKA

•

Heart rate, respiratory rate, and blood pressure every 4 hours until resolution of DKA
(normalization of bicarbonate or venous pH), then per routine

• Input and output should be accurately measured
Moderate/Severe DKA
•
•
•

Hourly heart rate, respiratory rate, and blood pressure (CR/sat monitors)
Hourly fluid input and output measured
Hourly neurologic assessment for warning signs of cerebral edema (headache, inappropriate
slowing of heart rate, recurrent vomiting, change in neurologic status, rising blood pressure,
decreased oxygen saturation).

Diagnostics:
DKA

•
•
•

Obtain hourly POC blood β-hydroxybutyrate
Hourly capillary blood glucose for patients on insulin drips and those receiving every 2 hour
correction doses of subcutaneous insulin.
Bicarbonate level (from BMP, iSTAT or VBG) will assist emergency department clinicians in
determining patient placement. Ongoing monitoring of BMP should be obtained every 4 hours
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Criteria for Floor and PICU admission stratified by age:
For Children < 5 years of age
Criteria for 6 Henson Admission:

•

Bicarbonate level > 10

Criteria for PICU Admission:

•

Patients at significant risk for cerebral edema (see risk factors under complications:
cerebral edema section of the synopsis) or

•
•
•

Neurologic signs that might indicate cerebral edema or
Bicarbonate level ≤ 10 mmol/L or
BUN level significantly elevated.

For Children > 5 years of age
Criteria for 6 Henson Admission:

•

Bicarbonate level > 5

Criteria for PICU Admission:

•

Patients at significant risk for cerebral edema (see risk factors under complications:
cerebral edema section of the synopsis) or

•
•
•

Neurologic signs that might indicate cerebral edema or
Bicarbonate level < 5 mmol/L
BUN level significantly elevated.

Treatment:
Moderate/Severe DKA
1. If patient is exhibiting critical organ failure (such as shock, respiratory failure,
cerebral edema, etc.) follow PALS resuscitation guideline until stable.
2. Fluid and electrolyte replacement

•

•

•

Administer 10 mL/kg IV bolus of isotonic crystalloid over 1 hour (maximum bolus 1 liter).
In severe dehydration a second fluid bolus of 10 mL/kg over 1 hour may be necessary.
After the fluid bolus is administered begin 1.5 maintenance IV fluid (IVF) of normal
saline.
Patients in DKA are inherently potassium and phosphorus depleted and will require
replacement therapy regardless of current levels of electrolytes on lab. If hypokalemic at
presentation, begin potassium therapy at time of initial volume expansion. Use caution in
replacing potassium in patients with hyperkalemia or renal failure. Verify these patients
are able to void prior to initiation of therapy. Contact the Endocrinologist on Call.
1.5x maintenance fluids should be changed to Normal Saline (NS) with 20 mEq/L K
acetate and 20 mEq/L K Phosphate as soon as available.

•
•

An additional IVF bag of D10 NS , 20 mEq/L K Acetate and 20 mEq/L K Phosphate
should be ordered to the bedside for use as indicated below under “continuous IV insulin
infusion” and/or “rapid acting subcutaneous insulin”.
NPO
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3.

Insulin initiation

a.

Basal subcutaneous insulin: Basal insulin should be given as soon as possible and
may be administered while a patient is on continuous IV insulin infusion. This injection
aids in the transition to subcutaneous dosing at DKA resolution, and only plays a small
role in DKA treatment

•

New-onset diabetes– administer subcutaneous insulin glargine:

•
•
•
•

0-4 years = 0.2 units/kg
5-7 years = 0.3 units/kg
8-10 years = 0.4 units/ kg
11 and up = 0.5 units/kg

•

b.

Known diabetes patient – if patient is connected to an insulin pump, it should be
disconnected. Then administer glargine insulin based on the above “new-onset
diabetes” recommendations. If patient is on injections administer home dose of
glargine or use above “new-onset diabetes” recommendations if home dose is
unknown.
Continuous IV insulin infusion:

•
•

0.1 units/kg/hour of IV regular insulin
Monitor capillary blood glucose hourly. Follow the titration table below and adjust NS
with additives and D10 NS with additives fluids based on blood glucose.
DKA Titration Schedule

Plasma
Glucose
> 250
200-249
150-199
< 150

•

BAG 1
BAG 2
Given as Percentages
NS
D10 NS
w/ additives
w/ additives
100%
50%
25%
0%

Final Dextrose
Concentration

0%
50%
75%
100%

0%
5%
7.5%
10%

If blood glucose drops between 80 to 99 mg/dL decrease IV insulin to
0.05units/kg/hour and contact the Supervising Physician.

•

If blood glucose drops < 80 mg/dL stop IV insulin, follow hypoglycemia protocol
located under supportive documents (see page 13), and contact Supervising
Physician.

•
•

Continue IV insulin infusion until bicarbonate level is ≥18mmol/L AND 1) anion gap is
normalized, or 2) POC blood ketones are <0.6 mmol/L.
Revision added 1/27/14: Upon discontinuing IV insulin, discontinue D10NS
with additives if patient’s blood glucose is stable.
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Mild DKA

1.

Fluid and electrolyte replacement

•
•

•
•
•

Administer 10 mlL/kg IV bolus of isotonic crystalloid over 1 hour (maximum bolus 1
liter) followed by 1.5 maintenance fluids of normal saline (International Diabetes
Federation, 2010 & Wolfsdorf, Glaser, & Sperling, 2006).
Patients in DKA are inherently potassium and phosphorus depleted and will require
replacement therapy regardless of current levels of electrolytes on lab. If hypokalemic
at presentation, begin potassium therapy at time of initial volume expansion. Use
caution in replacing potassium in patients with hyperkalemia or renal failure. Verify
these patients are able to void prior to initiation of therapy, and contact the
Endocrinologist on Call.
1.5x maintenance fluids should be changed to NS with 20 mEq/L K Acetate and 20
mEq/L K Phosphate as soon as available.
An additional IVF bag of D10 NS , 20 mEq/L K Acetate and 20 mEq/L K Phosphate
should be ordered to the bedside for use as indicated below under “continuous IV
insulin infusion” and/or “rapid acting subcutaneous insulin”.
NPO with ice chips initially. If patient clinically appears well and would like to eat,
they may do so, but they must receive the appropriate dose of insulin for
carbohydrates consumed. This dose may be found in their diabetes clinic visit or

2.

inpatient consultation records.
Insulin initiation
a. Basal subcutaneous insulin:
Basal insulin should be given as soon as possible and may be administered while a
patient is on continuous IV insulin infusion. This injection aids in the transition to
subcutaneous dosing at DKA resolution, and only plays a small role in DKA treatment

•

•

b.

New-onset diabetes– administer subcutaneous insulin glargine:

o
o
o
o

0-4 years = 0.2 units/kg
5-7 years = 0.3 units/kg
8-10 years = 0.4 units/ kg
11 and up = 0.5 units/kg

Known diabetes patient – if patient is connected to an insulin pump, it should be
disconnected. Then administer glargine insulin based on the above “new-onset
diabetes” recommendations. If patient is on injections administer home dose of
glargine or use above “new-onset diabetes” recommendations if home dose is
unknown.
Continuous IV insulin infusion:

•

•

Preferred treatment for mild DKA is IV regular insulin. IV insulin may be utilized on
the medical/surgical floors for mild DKA. However, staffing and bed availability may
make this option unavailable in which case rapid acting subcutaneous insulin is an
effective alternative.
0.1 units/kg/hour of IV regular insulin
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•

Monitor capillary blood glucose hourly. Follow the titration table below and adjust NS
with additives and D10 NS with additives fluids based on blood glucose.
DKA Titration Schedule

Plasma
Glucose

BAG 1
BAG 2
Given as Percentages
NS
D10 NS
w/ additives
w/ additives

> 250
200-249
150-199
<150

•

100%
50%
25%
0%

0%
50%
75%
100%

Final Dextrose
Concentration
0%
5%
7.5%
10%

If blood glucose drops between 80 to 99 mg/dL, decrease IV insulin to 0.05
units/kg/hour, and contact Supervising Physician.

•

If blood glucose drops < 80 mg/dL, stop IV insulin, follow hypoglycemia protocol
located under supportive documents (see page 13), and contact Supervising Physician.

•
•
c.

Continue IV insulin infusion until bicarbonate level is ≥18mmol/L AND either 1)anion
gap is normalized, or 2) blood ketones <0.6mmol/L.

Revision added 1/27/14: Upon discontinuing IV insulin, discontinue D10NS
with additives if patient’s blood glucose is stable.
Rapid acting subcutaneous insulin:

•

Rapid acting insulin (lispro, aspart, glulisine) should be administered 0.2 units/kg
subcutaneously every 2 hours

•

Monitor capillary blood glucose hourly. Follow the titration table below and adjust NS
with additives and D10 NS with additives fluids based on blood glucose.
DKA Titration Schedule

Plasma
Glucose
> 250
200-249
150-199
< 150

•

•

BAG 1
BAG 2
Given as Percentages
NS
D10 NS
w/ additives
w/ additives
100%
50%
25%
0%

0%
50%
75%
100%

Final Dextrose
Concentration
0%
5%
7.5%
10%

If blood glucose drops < 80 mg/dL follow hypoglycemic protocol located under
supportive documents (see page 13) and contact Supervising Physician. Do not
administer additional subcutaneous insulin until speaking with the Supervising
Physician.
Continue every 2 hour subcutaneous rapid acting insulin until bicarbonate level is
≥ 17mmol/L AND either 1)anion gap is normalized, or 2) blood ketones < 0.6mmol/L.
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Complications of DKA
1. Cerebral edema

o
o

Those at increased risk include younger age, new onset diabetes, and longer
duration of symptoms.
Additional risk factors at diagnosis or during treatment include – more severe acidosis,
very elevated BUN at presentation, use of bicarbonate for treatment of acidosis, fluid
bolus volume over 40 mL/kg given in the first 4 hours of treatment, a n d
administration of insulin in the first hour of fluid treatment (International Diabetes

o

Federation, 2010 & Wolfsdorf, Glaser, & Sperling, 2006).
Signs and symptoms – headache, slowing or irregular heart rate, change in
neurologic status (restlessness, irritability, increased drowsiness, and /or
incontinence), cranial nerve palsies or other specific neurologic signs, increasing

o

blood pressure, decreased oxygen saturation.
One diagnostic criterion, 2 major criteria, or one major and 2 minor criteria have a
sensitivity of 92% and a false positive rate of only 4% for detecting cerebral edema
(Muir, Quisling, Yang, & Rosenbloom, 2004).



o

Diagnostic criteria – abnormal motor or verbal response to pain, decorticate or
decerebrate posture, cranial nerve palsy, abnormal neurogenic respiratory
pattern (grunting, tachypnea)
 Major criteria – altered mental status, fluctuating level of consciousness,
sustained heart rate deceleration (decrease more than 20 beats per minute)
not attributable to improved hydration or sleep, age-inappropriate
incontinence
 Minor criteria – vomiting, headache, lethargy, diastolic BP >90 mm Hg, age
<5 years.
Medical/Surgical Treatment:



Contact and begin immediate transfer to critical care unit:

•
•
•
•

2.
3.
4.
5.

Elevate head of bed
Reduce fluid rate by 1/3 to ½
Begin medication therapy with one of the two options below
•
•

Mannitol 0.5-1 g/kg IV over 20 minutes
Hypertonic saline (3%), 5-10 mL/kg over 30 minutes

Obtain CT head after treatment has been started to rule out other
possible intracerebral causes of neurologic deterioration (thrombosis or
hemorrhage). If cerebal edema is suspected treatment should
precede imaging studies!
Hypokalemia – may precipitate cardiac arrhythmia, cardiac monitoring is recommended
Hypoglycemia – increase dextrose in IVF to treat, additionally see hospital guidelines for
treatment of hypoglycemia in diabetics under supporting documents (see page 13)
Hypophosphatemia
Pancreatitis

Discharge Criteria for DKA:

•

Resolution of DKA: bicarbonate ≥18mmol/L ORvenous pH >7.3, WITH normal (closed)
anion gap, or blood ketones <0.6mmol/L.
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Outcome Measures:
Time duration to resolution of DKA based on severity Number of
PICU admissions
Frequency of hypoglycemia
Potential cost savings with decreased PICU admissions and lab utilization
Potential Cost Implications:
Potential cost savings with decreased PICU admissions and lab utilization
Potential Organizational Barriers:
Acquisition of ketone meters
Training staff on use of new protocol and new equipment
Clinical Questions Answered:
Question 1: In the pediatric patient presenting with DKA which route of insulin therapy, intravenous
or subcutaneous, is most efficacious in resolving DKA as evidenced by a:
• normalized pH,

•
•
•
•
•
•
•

bicarbonate,
B-hydroxybutyrate,
negative urine ketones,
length of hospitalization,
duration of treatment until resolution of DKA (hrs),
duration of therapy until hyperglycemia < 200 - 250 mg/dL, and
amount of insulin (units) until resolution of DKA.

DKA Team Recommendations:
The DKA Team STRONGLY RECOMMENDS based on moderate-quality evidence the administration of insulin, via
the intravenous route, to children. We value improving DKA symptoms in children safely and effectively while
reducing the amount of painful procedures to this population at the same time. Data from Ersoz (2006), Fisher et
al. (1977), Umpierrez, Cuervo, et al. (2004), and Umpierrez, Latif, et al. (2004) demonstrate that insulin drip
therapy is as effective as subcutaneous insulin therapy. Fisher et al. (1977) reports a significant increase observed
in the rate of plasma glucose and total ketone bodies with intravenous insulin versus subcutaneous within the first
two hours of insulin administration; however, data was presented in a figure leaving the EBP Scholars unable to
table this outcome.
Literature (see Appendix A) supporting this recommendation:
Literature was searched. Fourteen citations were found from the search with five citations appearing to answer
the question; however, only four (Ersoz, et al., 2006; Fisher, et al., 1977; Umpierrez, Cuervo, et al., 2004;
Umpierrez, Latif, et al., 2004) articles address the specific question.
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Supporting tools
Informational Tools: Types of Insulin see Table 1.
Table 1. Types of Insulin
Type of Insulin

Onset of Action

Peak of Action

Total Duration

10-15 minutes

30-90 minutes

2-3 hours

30-60 minutes

2-4 hours

6-9 hours

1-2 hours

3-8 hours

12-15 hours

Glargine

1-2 hours

No peak

24 hours

Determir

1-2 hours

No peak

16-24 hours

70/30 NPH/regular

30-60 minutes

3-8 hours

12-15 hours

75/25 NPH/lispro

10-15 minutes

30min-8hours

12-15 hours

Rapid acting
Aspart, lispro, glulisine
Short acting
Regular
Intermediate acting
NPH
Long Acting

Premixed

Procedures:

1.
2.
3.
4.

Hypoglycemia (see page 13)
New Onset Diabetes (see page 14)
Known Diabetic with Diabetic Ketoacidosis (see page 15)
Known Diabetic at Risk for Diabetic Ketoacidosis (see page 16)
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Hypoglycemia

1.

Patients currently in DKA on IV insulin drip:

a.

Blood glucose < 80 mg/dL

i.

Stop insulin drip. Maximize D10 NS with additives IV fluids if not already at 100%.
Recheck glucose in 15 minutes. If > 80 mg/dL continue current management and
contact Supervising Physician. If blood glucose remains < 80 mg/dL treat with:

1.

2.
2.

If patient is alert and oriented without nausea/vomiting treat the patient with 15
grams of simple carbohydrate to eat/drink: 4 ounces of fruit juice, 5-6 ounces of
non-caffeinated regular soda, 6-7 saltine crackers, or 1 package of snack size
crackers. Recheck blood glucose in 15 minutes. If blood glucose is < 80 mg/dL
repeat treatment and contact Supervising Physician.
If patient is not able to cooperate and swallow safely and has IV access
administer either D10W 5 mL/kg bolus IV through peripheral IV, if central line
present may administer D25W 1 ml/kg bolus IV.

Patients on subcutaneous insulin:

a.

Blood glucose <80 mg/dL

i.

Mild hypoglycemia:

1.
2.

ii.

Signs/symptoms (shaky, weak, tired, hungry, irritable, or difficulty focusing), but
alert enough to safely take oral fluids/solids.
Administer 15 grams of simple carbohydrate to eat/drink: 4 ounces of fruit juice,
5-6 ounces of non-caffeinated regular soda, 6-7 saltine crackers, or 1 package of
snack size crackers. Recheck blood glucose in 15 minutes and repeat above steps
if still hypoglycemic. If blood glucose does not increase to
> 80 mg/dL within 30 minutes contact Supervising Physician.

Moderate to severe hypoglycemia:

1.

Signs/symptoms (pale, sweaty, confused, distant, poor coordination, slurred
speech, difficulty cooperating, altered mental status, semi-conscious,
unconscious, or seizing).

2.

If patient is able to cooperate, follow directions, and swallow safely administer 15
grams of simple carbohydrate to eat/drink: 4 ounces of fruit juice, 5-6 ounces of
non-caffeinated regular soda, 6-7 saltine crackers, or 1 package of snack size
crackers. Recheck blood glucose in 15 minutes and repeat above steps if patient
remains hypoglycemic. If blood glucose does not increase to > 80 mg/dL within 30
minutes contact Supervising Physician.

3.

If patient is not able to cooperate and swallow safely and has IV access
administer either D10W 5 ml/kg bolus IV through peripheral IV, if central line
present may administer D25W 1 ml/kg bolus IV.

4.

If patient does not have IV access give glucagon IM injection.

a.
b.

0.5 mg IM for <6 y/o.
1 mg IM for 6 y/o and older.
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New Onset Diabetes

1.
2.

Begin management of DKA as per clinical practice guidelines if patient meets DKA criteria.

3.

If patient is not in DKA the following guidelines should be used:

Obtain the following labs: Antibodies (IA-2 Ab, GAD-65 Ab, zinc transporter Ab, insulin Ab), c-peptide, TSH
Diagnostic Algorithm, and Celiac Diagnosic Algorithm

a.

Insulin

i.

ii.

Administer long acting insulin (insulin glargine) subcutaneously if not already done.
Bedtime administration is preferred if patient is not currently in DKA. For patients
presenting in DKA, basal insulin doses are as above

1.
2.
3.

5 to 10 years: 0.25 units/kg every 24 hours
> 10 years: 0.3 units/kg every 24 hours

Initiate subcutaneous rapid acting insulin (lispro, aspart, glulisine) based on insulin to
carbohydrate ratio for meals and snacks.

1.
2.

iii.

< 5 yoa: 0.2 units/kg every 24 hours

Patients < 5 y/o administer 1 unit for every 30 grams of carbohydrate (consider
dosing after the meal/snack)
Patients 5 y/o or older administer 1 unit for every 15 grams of carbohydrate
(pre meal dosing is preferred).

Correction doses

1.

2.

If blood glucose is above prescribed threshold prior to a meal administer a
correction dose of subcutaneous rapid acting (lispro, aspart, glulisine) insulin based
on insulin sensitivity factor (ISF).
1800
ISF =
𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑋𝑋2
If patient is < 5 yoa contact Endocrinologist on Call prior to administering
correction doses.

b.
c.
d.
e.
f.

Glucose monitoring

i.

Finger stick capillary glucoses should be obtained before meals, 2 hours after meals,
and 3 am.

Ketone monitoring

i.

Continue monitoring blood or urine ketones until negative and then monitor only for
BG > 240 mg/dL or with vomiting/abdominal pain

IV Fluids

i.

Saline lock IV once DKA resolved.

Carbohydrate Counting Diet
Diabetes education

i.
ii.

Provided in either the ambulatory or inpatient settings depending on patient circumstances.
Discuss with endocrinologist on-call to determine education disposition.
Refer to public website for educational materials available to families.
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Known Diabetic with Diabetic Ketoacidosis
Begin management of DKA as per clinical practice guidelines.

1.

Upon resolution of DKA the following guidelines should be used:

a.

Patients on Pumps:

i.
ii.
iii.
iv.

b.

ii.

A temporary basal rate of 0% will be programmed to expire approximately 24 hours
after last dose of insulin glargine has been administered.
All further insulin administration should occur via rapid acting insulin from the pump once
reconnected (for example basal insulin, meal boluses and correction boluses).
The home basal insulin (glargine, detemir, degludec) should be continued every 24
hours moving toward the home schedule for dosing (typically bedtime).
The home rapid acting insulin (lispro, aspart, glulisine) should be administered based on
the insulin to carbohydrate ratios and insulin sensitivity factors used at home for meals
and snacks.

Correction doses:

i.

Once pump is connected by Endocrine Team, the patient may enter their pre meal finger
stick blood glucose results along with their grams of carbohydrate into their pumps for
correction doses to be administered with their mealtime insulin.

ii.

Patients on MDI may use an insulin sensitivity factor (ISF) to calculate correction
doses to be administered along with their mealtime insulin if blood glucose is
>240mg/dL prior to a meal. If a patient’s ISF at home is 1:50, then 1 unit of rapid
acting insulin will drop the blood glucose 50 points. To calculate a correction dose take
the patient’s blood glucose subtract 100 (the target glucose) and divide by the ISF.
Example: Patient’s blood glucose is 350 mg/dL and ISF is 1:50 350
(current glucose)-100 (target glucose) = 250 250÷50
(ISF) = 5 units of rapid acting insulin
Add the 5 units to the mealtime dose for the total dose.
Discuss doing correction doses with the Endocrinologist on call before administering to
patients on MDI.

iii.

d.

If the patient does not have additional infusion sets they should be retrieved from home as
these are not available from our pharmacy.

Patients on Multiple Daily Injections (MDI):

i.

c.

Endocrinologist and/or diabetes educator should assess the pump and reconnect it to
the patient after a new infusion set has been placed.

If ISF is not known:
ISF =

1800
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑜𝑜𝑜𝑜 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼

Diabetes education:
Home sick day and/or ketone management should be reviewed with the patient by a diabetes
educator prior to discharge.
i. Assess need for social work or psychology involvement.
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Known Diabetic at Risk for Diabetic Ketoacidosis
For diabetic patients with bicarbonate level 16-19 mmol/L, glucose >240 mg/dL, and moderate to large urine
ketones or blood ketones ≥ 1.5 mmol/L the following guidelines should be used:
1. Contact Endocrinologist on Call.
2. Fluids: If patient is nauseated or vomiting and unable to take oral fluids administer 10 ml/kg NS
bolus over 1 hour.
3. Medications:
a. Ondansetron
i. Consider if patient is severely nauseated or vomiting.
1. >2 y/o 0.1 mg/kg sublingual or IV.
2. >40 kg give 4 mg sublingual or IV.
b. Insulin
i. Administer a correction dose of rapid acting insulin (aspart, lispro, glulisine) with a
syringe via subcutaneous injection.
1. 0.1 units/kg for moderate ketones.
2. 0.2 units/kg for large ketones.
ii. A second correction dose may be given based on above guidelines if blood glucose 2
hours post correction dose has not decreased >100 mg/dL and remains > 240 mg/dL.
iii. If patient is on an insulin pump have the patient remove their current insulin infusion set
and replace it with a new infusion set in a different site (ie opposite leg, buttock, arm,
etc.). If this cannot be done in the ED and patient is stable for discharge the site change
should occur immediately upon discharge at home. Ketone/DKA correction doses MAY
NOT be given through insulin pump.
4. Monitoring:
a. Blood glucose
i. Finger stick glucose should be obtained 2 hours after a correction dose is
administered.
1. If glucose 2 hours post correction dose has decreased >100 mg/dL or is normal
and patient is symptomatically improved consider discharge to home.
2. If glucose 2 hours post correction dose has not decreased >100 mg/dL and remains
> 240 mg/dL repeat correction dose as above.
5. Disposition:
a. If patient is symptomatically improved and blood glucose has decreased > 100 mg/dL or is
normal after correction dose(s) contact Endocrinologist on Call for discharge to home
instructions.
i. Give appropriate care card to patient (sick day management, ketones on a pump,
ketones on injections, etc.).
b. If patient is still symptomatic and blood glucose has not significantly improved contact
Endocrinologist on Call.
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Guideline Preparation: This guideline was prepared by The Office of Evidence Based Practice (EBP) in
collaboration with content experts at The Children’s Mercy Hospitals. Development of this guideline supports the
initiative of the Department of Clinical Effectiveness to promote care standardization that builds a culture of
quality and safety that is evidenced by measured outcomes. If a conflict of interest is identified, the conflict will
be disclosed next to the team member’s name.
Team Members:
• Team Leaders:

o
o

Ryan McDonough, DO, Endocrinologist
Tiffany Musick, DO, Endocrinologist

• Team Members:
•

o

Susette Porazik-Ball, BSN, RN, CCRN – CMS ED Critical Care Education Coordinator
IS Team Members:

Office of EBP Team Members:

o
o
o

J. Michael, DO, EBP Medical Director
J. Bartlett, PhD, RN, Evidence Based Practice Director
K. Swaggart, MLIS, Medical Librarian

Guideline development funded by:
No external funding was obtained in the development of this guideline.
Development Process:
The review summary documents the following steps:

1.

Review of existing internal and external guidelines and standards
a. Internal guidelines: CMHC DKA guidelines
b. External guidelines:
International Diabetes Federation. (2010). Global IDF/ISPAD guidelines for Type 1 diabetes in childhood
and adolescence. Retrieved from http://www.fdgdiabete.it/public/draft_idf_2010.pdf
Wolfsdorf, J., Glaser, N., & Sperling, M. A. (2006). Diabetic ketoacidosis in infants, children, and adolescents: A
consensus statement from the American Diabetes Association. Diabetes Care, 29(5), 1150-1159. doi: 29/5/1150 [pii]
10.2337/diacare.2951150
2. Review preparation
a. PICOT (Patient, Intervention, Comparison, Outcome, Type of question) questions established
b. Team leaders confirmed search terms employed by the Health Science Medical librarians, reviewed
article titles and abstracts from the search, and identified articles to be read and synthesized by the
Evidence Based Practice Scholars.
3. Databases searched
a. AHRQ National Guideline Clearinghouse
b. Cochrane
c. Medline
d. CINAHL
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4.

5.

Critically analyze the evidence
a. Guidelines
i. AGREE criteria were used to analyze published clinical guidelines.
b. Single studies
i. The EBP Scholars used the Cochrane Collaborative’s electronic software, Review Manager 5
(RevMan), to produce systematic reviews of the evidence of the effects of healthcare and delivered
these documents to the team for review. RevMan allowed the EBP Scholars to build the tables of
study characteristics, tables of study biases, and analyze study data in a meta- analysis. . In
instances when RevMan could not be used, CASP (Critical Appraisal Skills Programme) tools were
utilized to analyze the literature.
ii. When a meta-analysis was found in the literature search, or created in RevMan, the GRADE criteria
evaluated the literature using the Cochrane Collaborative’s electronic software known as
GRADEprofiler (GRADEpro). GRADEpro assesses the meta-analysis for:
1. Limitations in study design and execution
2. Inconsistency between studies
3. Indirectness of study outcomes
4. Imprecision
5. Publication bias
Recommendations for the guideline were developed by a consensus process incorporating the three principles of
EBP (current literature, content experts [CPG Team], and patient and family preference [when possible]).

Approval Process: Guidelines are reviewed and approved by the CPG Team comprised of content expert clinicians,
the Office of EBP, and other appropriate hospital committees as deemed suitable for the guideline’s intended use.
Guidelines are reviewed and updated as necessary every 3 years within the Office of EBP at CMH&C. The CPG Team
will be involved with every review and update.
Disclaimer:
The content experts and the Office of EBP are aware of the controversies surrounding the management of the
pediatric patient in DKA. When evidence is lacking or inconclusive, options in care are provided in the guideline and
the power plans that accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly
these guidelines should guide care with the understanding that departures from them may be required at times,
although a discussion with an Endocrinologist is recommended prior to this occurring

The Office of Evidence Based Practice, 2021
Service & Performance Excellence

17

Initial April 29, 2013; Revisions: 4/13; 1/14; 9/14; 12/14; 12/15,
12/16;11/19
References
Ersoz, H. O., Ukinc, K., Kose, M., Erem, C., Gunduz, A., Hacihasanoglu, A. B., & Karti, S. S. (2006).
Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of
mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract, 60(4), 429-433. doi:
10.1111/j.1368-5031.2006.00786.x
Ferguson, A. M., Michael, J., Bartlett, J. A., Barnes, M., DeLurgio, S., Turpin, A., Garg, U., & Clements, M. (2015, July
26-30). Establishing a point-of-care β-Hydroxybutyrate concentration to initiate treatment of pediatric diabetic
ketoacidosis. American Association for Clinical Chemistry: 2015 Annual Meeting & Clinical Lab Expo. Atlanta,
GA.
Fisher, J. N., Shahshahani, M. N., & Kitabchi, A. E. (1977). Diabetic ketoacidosis: low-dose insulin therapy by various
routes. N Engl J Med, 297(5), 238-241. doi: 10.1056/NEJM197708042970502
International Diabetes Federation. (2010). Global IDF/ISPAD guidelines for Type 1 diabetes in childhood and
adolescence. Retrieved from http://www.fdgdiabete.it/public/draft_idf_2010.pdf
Rewers, A., McFann, K., & Chase, H. P. (2006). Bedside monitoring of blood beta-hydroxybutyrate levels in the
management of diabetic ketoacidosis in children. Diabetes Technol Ther, 8(6), 671-676. doi:
10.1089/dia.2006.8.671
Rogers, M. A. M., Kim, C., Banerjee, T. & Lee, J. M. (2017). Fluctuations in the incidence of type 1 diabetes in the
United States from 2001 to 2015: A longitudinal study. BMC Med 199. doi:10.1186/s12916-017-0958-6
Trachtenbarg, D. E. (2005). Diabetic ketoacidosis. American Family Physician, 71(9), 1705-1714.
Umpierrez, G. E., Cuervo, R., Karabell, A., Latif, K., Freire, A. X., & Kitabchi, A. E. (2004). Treatment of diabetic
ketoacidosis with subcutaneous insulin aspart. Diabetes Care, 27(8), 1873-1878.
Umpierrez, G. E., Latif, K., Stoever, J., Cuervo, R., Park, L., Freire, A. X., & A, E. K. (2004). Efficacy of subcutaneous
insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic
ketoacidosis. Am J Med, 117(5), 291-296. doi: 10.1016/j.amjmed.2004.05.010
Voulgari, C., & Tentolouris, N. (2010). The performance of a glucose-ketone meter in the diagnosis of diabetic
ketoacidosis in patients with type 2 diabetes in the emergency room. Diabetes Technol Ther, 12(7), 529- 535.
doi: 10.1089/dia.2010.0011

The Office of Evidence Based Practice, 2021
Service & Performance Excellence

18

Initial April 29, 2013; Revisions: 4/13; 1/14; 9/14; 12/14; 12/15, 12/16; 11/19
Appendix A
Question 1: In the pediatric patient presenting with DKA which route of insulin therapy, intravenous or subcutaneous, is most efficacious in
resolving DKA as evidenced by a:

•
•
•
•
•
•
•
•

normalized pH,
bicarbonate,
B-hydroxybutyrate,
negative urine ketones,
length of hospitalization,
duration of treatment until resolution of DKA (hrs),
duration of therapy until hyperglycemia < 200 - 250 mg/dL, and
amount of insulin (units) until resolution of DKA.

GRADEprofiler Table:
Quality assessment
No of
studies

Design

Risk of bias

Inconsistency

Indirectness

Effect

No of patients

Imprecision

Other
considerations

Subcutaneous
Insulin

Continuous
Intravenous
Insulin

Quality
Absolute

pH >7.3 (h) (Better indicated by lower values)
21,2

RCT

Very serious5

No serious
inconsistency

No serious
indirectness

Serious6

reporting bias

25

25

MD 1.94 lower (4.07
lower to 0.19 higher)

Serious8

reporting bias

25

25

MD 1.35 lower (4.36
lower to 1.65 higher)

Serious10

none

10

10

MD 4.1 lower (10.29
lower to 2.09 higher)

Serious12

none

10

10

MD 5.1 lower (13.13
lower to
2.93 higher)

⊕ΟΟΟ
VERY LOW

Bicarbonate > 15 - 18 mEq/l (h) (Better indicated by lower values)
21,2

RCT

Very serious7

No serious
inconsistency

No serious
indirectness

⊕ΟΟΟ
VERY LOW

B-hydroxybutyrate <0.6mmol/l (h) (Better indicated by lower values)
11

RCT

Very serious9

No serious
inconsistency

No serious
indirectness

Urine Ketone Negative (h) (Better indicated by lower values)
No serious
No serious
inconsistency
RCT
Very serious11
11
indirectness
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Hospital Stay (days) (Better indicated by lower values)
23,4

RCT

No serious risk of
No serious
bias inconsistency

No serious
indirectness

Serious13

none

35

35

MD 0.19 lower
(1.08 lower to 0.7
higher)

Duration of treatment until resolution of DKA (hrs) (Better indicated by lower values)
23,4

RCT

No serious risk of No serious
bias
inconsistency

No serious
indirectness

Very
serious14

MD 1 lower (2.53
lower to 0.53
higher)

⊕⊕⊕Ο
MODERATE

Low

none

35

35

none

60

60

MD 0.22 lower
(1.42 lower to
0.97 higher)

Low

none

60

60

MD 6.45 lower
(14.07 lower to
1.16 higher)

Low

Duration of therapy until hyperglycemia < 200 - 250 mg/dL (hr) (Better indicated by lower values)
41,2,3,4

RCT

Serious15

No serious
inconsistency

No serious
indirectness

Serious16

Amount of insulin (units) until resolution of DKA (Better indicated by lower values)
41,2,3,4

RCT

Serious17

No serious
inconsistency

No serious
indirectness

Serious18

Ersoz (2006).
Fisher (1977).
3
Umpierrez Cuervo (2004).
4
Umpierrez Latif (2004).
5
For the Ersoz (2006) and Fisher (1977) articles the author's did not describe how risk of bias was minimized.
6
The combined sample size between the Ersoz (2006) and Fisher (1977) articles is 50 which could lead to statistical imprecision.
7
Same as footnote 5.
8
Same as footnote 6.
9
Ersoz (2006) did not describe how risk of bias was minimized.
10
The sample size (N=20) is small which could compromise statistical precision.
11
Same as footnote 9.
12
Same as footnote 10.
13
Between the two studies the sample size (N=70) is small which could compromise statistical precision.
14
Same as footnote 13.
15
Two of the articles (Ersoz, 2006; Fisher 1977) did not describe how risk of bias was minimized while the other two articles (Umpierrex, Cuervo, 2004; Umpierrez, Latif, 2004) did describe how risk of bias
was minimimized.
16
Between the four studies the sample size (N=120) which is smaller than the standardized Cochrane acceptable sample size (N=400); with smaller sample sizes statistical precision can be compromised.
17
Same as footnote 15.
18
Same as footnote 16.
1
2

Synthesis Author(s): EBP Scholars (Bartlett, J. A., Dusin, J. D., Gutierrez, C. L., & Shubat, S. J.)
Date: 2011-11-23
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Forest Plots of Comparisons
Subcutaneous Insulin vs. Continuous Intravenous Insulin, outcome: pH >7.3 (h).
Experimental--DripControl--SQ
Mean Difference
Study or SubgrouM
p ean SD TotalMean SD TotalWeight IV, Fixed, 95% CI
Ersoz 2006
Fisher 1977

6.8
8.7

5.7
4.11

Total (95% CI)

10
15

8.2 5.6
6 2.19

25

Mean Difference
IV, Fixed, 95% CI

10 18.5%-1.40 [-6.35, 3.55]
15 81.5% 2.70 [0.34, 5.06]
25 100.0%1.94 [-0.19, 4.07]

Heterogeneity: Chi² = 2.15, df = 1 (P = 0.14); I² = 53%
Test for overall effect: Z = 1.79 (P = 0.07)

-10 -5
10
Favours Drip Favours SubQ

Subcutaneous Insulin vs Continuous Intravenous Insulin, outcome: Bicarbonate > 15 - 18 mEq/l (h).
Subcutaneous InsuliC
n ontinuous IV Insulin
Mean Difference
Study or SubgroupMean
SD Total Mean
SD TotalWeight IV, Fixed, 95% CI

Ersoz 2006
Fisher 1977
Total (95% CI)

14.8
10.8

7
3.01

10
15

13.2
13

7.5
6.02

25

Mean Difference
IV, Fixed, 95% CI

10 22.3% 1.60 [-4.76, 7.96]
15 77.7%-2.20 [-5.61, 1.21]
25 100.0%-1.35 [-4.36, 1.65]

Heterogeneity: Chi² = 1.07, df = 1 (P = 0.30); I² = 6%
Test for overall effect: Z = 0.88 (P = 0.38)

-4 -2 0 2 4
Favours--Drip
Favours--SQ

Subcutaneous Insulin vs Continuous Intravenous Insulin, outcome: B-hydroxybutyrate <0.6mmol/l (h).
Experimental--DripControl--SQ
Mean Difference
Study or SubgrouM
p ean SD TotalMean SD TotalWeight IV, Fixed, 95% CI
Ersoz 2006
15.3 8.7
10 11.2 4.9 10 100.0%4.10 [-2.09, 10.29]
10
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
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Mean Difference
IV, Fixed, 95% CI

10 100.0%4.10 [-2.09, 10.29]
-20 -10 0 10 20
Favours--Drip Favours--SQ

25

Initial April 29, 2013; Revisions: 4/13; 1/14; 9/14; 12/14; 12/15, 12/16; 11/19
Subcutaneous Insulin vs Continuous Intravenous Insulin, outcome: Urine Ketone Negative (h).
Experimental--DripControl--SQ
Mean Difference
Study or SubgrouM
p ean SD TotalMean SD TotalWeight IV, Fixed, 95% CI
Ersoz 2006
22.3 10.9 10 17.2 7 10 100.0%5.10 [-2.93, 13.13]
Total (95% CI)
10
Heterogeneity: Not applicable
Test for overall effect: Z = 1.24 (P = 0.21)

Mean Difference
IV, Fixed, 95% CI

10 100.0%5.10 [-2.93, 13.13]
-20 -10
20
Favours--Drip Favours--SQ

Subcutaneous Insulin vs Continuous Intravenous Insulin, outcome: Hospital Stay (days).
Experimental--DripControl--SQ
Mean Difference
Study or Subgroup Mean SD TotalMean SD TotalWeight IV, Fixed, 95% CI

Umpierrez Cuervo 20044.5
Umpierrez Latif 2004
4

1

Total (95% CI)

15
20

4

2

35

Mean Difference
IV, Fixed, 95% CI

15 17.2% 1.10 [-1.05, 3.25]
20 82.8% 0.00 [-0.98, 0.98]
35 100.0%0.19 [-0.70, 1.08]

Heterogeneity: Chi² = 0.83, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 0.42 (P = 0.68)

-4
-2
2
4
Favours--Drip Favours--SQ

Subcutaneous Insulin vs Continuous Intravenous Insulin, outcome: Duration of treatment until resolution of DKA (hrs).
Experimental--DripControl--SQ
Mean Difference
Study or Subgroup Mean SD TotalMean SD TotalWeight IV, Fixed, 95% CI

Umpierrez Cuervo 200411
Umpierrez Latif 2004 11
Total (95% CI)

4

15
20

10
10

3

35

Heterogeneity: Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 1.28 (P = 0.20)

The Office of Evidence Based Practice, 2019
Center of Clinical Effectiveness

Mean Difference
IV, Fixed, 95% CI

15 51.0% 1.00 [-1.15, 3.15]
20 49.0% 1.00 [-1.19, 3.19]
35 100.0%1.00 [-0.53, 2.53]
-4 -2
Favours--Drip

4
Favours--SQ
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Subcutaneous Insulin vs Continuous Intravenous Insulin, outcome: Duration of therapy until hyperglycemia < 200 - 250 mg/dL (hr).
Experimental--DripControl--SQ
Mean Difference
Study or Subgroup Mean SD TotalMean SD TotalWeight IV, Fixed, 95% CI

Ersoz 2006
12.7 7.5
Fisher 1977
6 3.83
Umpierrez Cuervo 20047.1
5
Umpierrez Latif 2004
7
2

10
15
15
20

Total (95% CI)

60

9.4 8.9
5.6 2.46
6.9 4
7
3

Heterogeneity: Chi² = 0.80, df = 3 (P = 0.85); I² = 0%
Test for overall effect: Z = 0.37 (P = 0.71)

Mean Difference
IV, Fixed, 95% CI

10 2.7%3.30 [-3.91, 10.51]
15 26.8% 0.40 [-1.90, 2.70]
15 13.5% 0.20 [-3.04, 3.44]
20 56.9% 0.00 [-1.58, 1.58]
60 100.0%0.22 [-0.97, 1.42]
-10 -5
0
10
Favours--Drip Favours--SQ

Subcutaneous Insulin vs Continuous Intravenous Insulin, outcome: Amount of insulin (units) until resolution of DKA.
Experimental--Drip Control--SQ
Mean Difference
Study or Subgroup Mean SD TotalMean SD TotalWeight IV, Fixed, 95% CI

Ersoz 2006
65.2 12.7
Fisher 1977
100 30.12
Umpierrez Cuervo 200482
28
Umpierrez Latif 2004 98
26

10 61.7 10.9 10 53.9% 3.50 [-6.87, 13.87]
15 85 21.91 15 16.3% 15.00 [-3.85, 33.85]
15 85 33 15 12.1%-3.00 [-24.90, 18.90]
20 84 32 20 17.7% 14.00 [-4.07, 32.07]

Total (95% CI)

60

Heterogeneity: Chi² = 2.49, df = 3 (P = 0.48); I² = 0%
Test for overall effect: Z = 1.66 (P = 0.10)

Mean Difference
IV, Fixed, 95% CI

60 100.0% 6.45 [-1.16, 14.07]
-20 -10 0 10 20
Favours--Drip Favours--SQ

Search strategy implemented:
PubMed performed October 22, 2010:
"Diabetic Ketoacidosis/drug therapy"[Majr] AND ("Insulin/administration and dosage"[Mesh] AND ("Infusions, Intravenous"[Mesh] OR "Injections,
Subcutaneous"[Mesh])) AND ("humans"[MeSH Terms] AND (systematic[sb] OR (Meta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR
Comparative Study[ptyp])) AND English[lang]) http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/18WEaBXD-u1n3n7ziwXvxqjQh/
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Characteristics of included studies
Ersoz 2006
Methods
Randomized Control Trial
Participants

Twenty patients with mild or moderate DKA (mean age 43.8 ± 19.0 years, 11 women and nine men) were enrolled in the
study.

Interventions

After a complete physical and laboratory evaluation, patients with a diagnosis of mild or moderate DKA were enrolled in the study.
The patients were randomly assigned into two groups. Following a bolus injection of 0.15 U/kg IV regular insulin, group L received
half of this dose as hourly SC insulin lispro, while group R was treated conventionally with standard IV regular insulin infusion.
Insulin dose was titrated according to serum glucose and pH levels. Both treatments were continued until all follow-up parameters
became normal.

Outcomes

Evaluate the efficacy and safety of hourly subcutaneous insulin lispo administration in the treatment of diabetic ketoacidosis in
comparison with intravenous regular insulin treatment. Time needed for normalization of serum glucose, B- hydroxybutyrate,
blood pH and urine ketone.
Patients with severe ketoacidosis were not included in the study population.

Notes
Risk of bias table

Bias

Scholar’s judgement

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding (performance bias and detection bias)

Support for judgement

Unclear Risk

Sequence generation was not described.

Unclear Risk

Allocation was not described

High Risk

Unable to blind patients or practitioners.

Incomplete outcome data (attrition bias)

Unclear Risk

None discussed.

Selective reporting (reporting bias)

Unclear Risk

None discussed.

Unclear Risk

None discussed.

Other bias
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Fisher 1977
Methods

Participants

Interventions

After initial evaluation and lab work in the ER, patients were brought to the Clinical Research Center where they were treated by
low-dose insulin therapy given either intramuscularly, subcutaneously, or by continuous intravenous infusion according to a
previously established randomized protocol. All insulin injections, subsequent blood chemical tests and medical procedures were
carried out in the Clinical Research Center of the University of Tennessee Center for the Health Sciences.
For admission to the protocol, patients had to meet all the following criteria: plasma glucose greater than 300mg per deciliter; blood
acetone positive at more than 1:2 dilution; blood pH less than 7.3; serum bicarbonate less than 15 mEq per liter; glycosuria(3+ test
or greater) with ketonuria. Informed consent was obtained in all cases before the patients were admitted to the Clinical Research
Center. A total of 45 patients were admitted to this protocol from October 1975 through September, 1976.
Venous blood was drawn at regular intervals for measurement of glucose, electrolytes, ketone bodies, cortisol, glucagon, pyruvate
and lactate, and arterial specimens were obtained for blood gases and pH. In patients who had not previously received insulin, blood
was obtained for measurement of immunoreactive insulin at the outset and during insulin therapy at 10-minute intervals for the first
hour and once every hour thereafter. The initial dose of crystalline insulin was administered, based on body weight (0.33 units per
kg), regardless of the initial plasma glucose as a bolus in a peripheral vein for the intravenous group. The other groups received
intramuscular and subcutaneous injections in the deltoid area with 3.8-cm and 1.3-cm needles, respectively. Patients who failed to
have at least a 10% fall in plasma glucose by the end of the first hour received repeat "loading" doses on a weight basis hourly until
a 10% decline in plasma glucose occurred. Thereafter, the dose of insulin in all three groups were arbitrarily set at 7 units per hour
until the plasma glucose reached 250mg per deciliter. The intravenous group received insulin as a continuous infusion in 0.9%
sodium chloride solution containing 2.5% human albumin. The intramuscular and subcutaneous groups received 7 units of regular
insulin hourly by the respective routes. Once plasma glucose reached 250mg per deciliter, dextrose in water or in saline was
substituted for the sodium chloride solution. If the ketoacidosis was still not under control (control being defined as bicarbonate
concentration higher than 15 mEq per liter, pH above7.3 and plasma acetone negative at 1:2 dilution), 4 to 12 units of regular
insulin was given every two hours by the same route as previously administered according to the amount of hyperglycemia or
glycosuria. No insulin was administered if the plasma glucose was less than 150mg per deciliter even in the presence of glycosuria.
Intravenous fluid and electrolyte replacement and the use of sodium bicarbonate was kept as similar as possible in all groups.
Potassium replacement was administered half as potassium chloride and half as potassium phosphate. All patients were kept in the
Clinical Research Center for 24 hours, even if the DKA was under control, to evaluate for hypoglycemia, hypokalemia or other
complications. Venous blood samples were obtained just before hourly insulin therapy and analyzed using a Beckman glucose
AutoAnalyzer. Serum acetone in serial dilution was measured by the nitroprusside method. Insulin was assayed by the doubleantibody radioimmunoassay method, glucagon by the use of Unger's 30-K antiserum, and cortisol by the fluorometric method.
Ketone bodies, pyruvate and lactate were measured by enzymatic procedures. All other chemical measurements were performed by
the Clinical Chemistry Laboratory. Calculation of statistical significance was by the Student t-test.
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Outcomes

As a result of the random assignment of patients on admission to one of the three treatment groups the average initial chemical
profile was remarkably similar, as were mean weights and ages. There was no significant difference in the number of hours
required to reach various biochemical endpoints. Little difference noted in the amount of fluid replacement or insulin therapy
administered. Of note is the significant increase observed in the rate of fall of both glucose and ketone bodies with intravenous as
compared to subcutaneous and intramuscular therapy during the first two hours. The ketone bodies actually rose during the first
hour of therapy in the latter two groups. Nine of forty-five patients failed to have at least a 10% fall in plasma glucose by the end
of the first hour, requiring a second loading dose of insulin (two in the intravenous group, three in the subcutaneous, and six in
the intramuscular group), whereas two patients, both in the intramuscular group, needed a third loading dose to achieve an
adequate initial response. After the second hour, however, no significant differences were observed in either the glucose or
ketone-body levels among the three routes of insulin administration.

Risk of bias table
Bias

Scholar’s judgement

Support for judgment

Random sequence generation (selection bias)

Unclear Risk

No description given.

Allocation concealment (selection bias)

Unclear Risk

No description given.

Blinding (performance bias and detection bias)

Unclear Risk

No description given.

Incomplete outcome data (attrition bias)

Unclear Risk

No description given.

Selective reporting (reporting bias)

Unclear Risk

No description given.

Other bias

Unclear Risk

No description given.
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Umpierrez Cuervo 2004
Methods
Prospective, randomized, open trial
Participants

45 consecutive adult patients with DKA

Interventions

Patients were randomly assigned in the emergency department to receive SC aspart insulin every hour (SC-1h, n=15)
or every 2 h (SC-2h, n=15), or to receive IV regular insulin (n=15).
-1
-1
Patients treated with SC-1h received an initial injection of 0.3 units/kg body wt, followed by 0.1 units kg X h
until blood
-1
-1
glucose reached 13.8 mmol/l (250 mg/dL). At that time, insulin dose was reduced reduced to 0.05 units kg X h
, and the IV
fluids were changed to D5% 0.45 saline to maintain blood glucose at 11.1 mmol/l (200 mg/dL) until resolution of DKA. Patients
treated with SC-2h received an initial dose of 0.3 units/kg followed by 0.2 units/kg 1 h later and every 2 h until blood glucose
reached 13.8 mmol/l (250 mg/dL). At that time, insulin dose was reduced to 0.1 units/kg every 2 h, and the IV fluids were
changed to D5% 0.45 saline to keep blood glucose at 11.1 mmol/l (200 mg/dL) until resolution of DKA. [This group's data is not
reported in this review.]
Patients treated with IV regular insulin received an initial bolus of 0.1 units/ kg, followed by a continuous infusion of regular
-1
-1
insulin calculated to deliver 0.1 units X kg X h
until blood glucose levels were 13.8 mmol/l (250 mg/dL). At that time, insulin
-1
-1
dose was reduced to 0.05 units kg X h
, and the IV fluids were changed to D5% 0.45 saline to maintain blood glucose at 11.1
mmol/l (200 mg/dL) until resolution of DKA.

Outcomes

1. Duration of treatment until resolution of hyperglycemia and ketoacidosis
2. Total length of hospitalization
3. Amount of insulin administration until resolution of hyperglycemia and ketoacidosis 3. Number of hypoglycemic events.

Notes

The diagnosis of DKA was established in the emergency department. Patients with: a plasma glucose level of 13.8 mmol/l (250
mg/dL), a serum bicarbonate level 15 mmol/l, a venous pH 7.30, and a positive serum ketone level at a dilution 1:4 by the
nitroprusside reaction, and/or a serum -hydroxybutyrate level 3.0 mmol/l. Patients excluded had: persistent hypotension
(systolic blood pressure 80 mmHg) after the administration of 1 liter of normal saline and patients with acute myocardial
ischemia, end- stage renal or hepatic failure, anasarca, dementia, or pregnancy.
Because of hospital regulations that did not allow the use of IV insulin drips outside the ICU, patients treated with IV regular
insulin were admitted to the ICU, whereas patients treated with SC aspart were managed in the general medicine floor or in a
step-down unit.
The authors did not define DKA resolution.
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Risk of bias table
Bias

Scholar’s judgement

Support for judgement

Random sequence generation (selection bias)

Unclear Risk

Insufficient information about the sequence generation process to
permit judgment

Allocation concealment (selection bias)

Unclear Risk

Insufficient information about the sequence generation process to
permit judgment

Blinding (performance bias and detection bias)

Low Risk

Though blinding did not occur the outcome and the outcome
measurement were not likely to be influence by lack of blinding

Incomplete outcome data (attrition bias)

Low Risk

No missing outcome data

Selective reporting (reporting bias)

Low Risk

Other bias

Low Risk

All of the study's pre-specified outcomes that were of interest were
reported
The study seems to be free of other sources of bias

Umpierrez Latif 2004
Methods
Participants

Randomized Control Trial
The sample comprised 40 patients with diabetic ketoacidosis who were recruited from the Atlanta Medical Center and the
University of Tennessee Health Science Center. [40 patients with DKA were assigned in the emergency department to
receive subcutaneous insulin lispro or intravenous regular insulin following a computer-generated randomization table.
The diagnosis of diabetic ketoacidosis was established in the emergency department using a plasma glucose level250
mg/dL (13.9 mmol/L), a serum bicarbonate level 15 mEq/L, a blood pH 7.3, a positive serum ketone level at a dilution
1:4 by the nitroprusside reaction, and a serum
-hydroxybutyrate level31 mg/dL (3 mmol/L). Pts were excluded who had persistent hypotension (systolic blood pressure
80 mm Hg) after the administration of 1 liter of normal saline, comatose state (loss of consciousness), acute myocardial
ischemia, heart failure, end-stage renal disease, anasarca, dementia, or pregnancy. Due to hospital regulations
disallowing the use of intravenous insulin outside the intensive care unit, patients treated with intravenous insulin were
admitted to the intensive care unit, while patients treated with subcutaneous lispro were managed on a general medicine
floor or in a stepdown unit.]

The Office of Evidence Based Practice, 2019
Center of Clinical Effectiveness

32

Initial April 29, 2013; Revisions: 4/13; 1/14; 9/14; 12/14; 12/15, 12/16; 11/19
Interventions

Insulin therapy arms:
1) Subcutaneous lispro every hour: Initial dose subcutaneously: 0.3 unit/kg of body weight, followed by Subcutaneous
lispro insulin at 0.1 unit/kg/h. When blood glucose levels 250 mg/dL, change intravenous fluids to dextrose 5% in
0.45% saline and reduce rate to 0.05 unit/ kg/h to keep glucose levels 200 mg/dL (11.1 mmol/L) until resolution of
diabetic ketoacidosis.
2) Intravenous regular insulin: a) Initial intravenous bolus: 0.1 unit/kg body weight, followed by. b) Continuous insulin
infusion at 0.1 unit/kg/h. When blood glucose levels 250 mg/dL, change intravenous fluids to dextrose 5% in 0.45%
saline and reduce rate to 0.05 unit/ kg/h to keep glucose levels 200 mg/dL (11.1 mmol/L) until resolution of diabetic
ketoacidosis.

Outcomes

Compare the efficacy and safety of subcutaneous insulin lispro with that of low-dose continuous intravenous regular
insulin in the treatment of patients with uncomplicated diabetic ketoacidosis. Ketoacidosis was considered resolved
when serum bicarbonate levels were ≥18 mEq/L and venous pH was ≥7.3.

Notes

Subcutaneous insulin lispro pts were managed in regular medicine wards or an intermediate care unit, while
intravenous protocol group were managed in the intensive care unit.

Risk of bias table

Bias

Scholar's judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Computer generated.

Allocation concealment (selection bias)

High risk

Unable to conceal allocation.

Blinding (performance bias and detection
bias)

High risk

Though blinding did not occur the outcome and the outcome
measurement were not likely to be influence by lack of blinding

Incomplete outcome data (attrition bias)

Low risk

All of the study's pre-specified outcomes that were of interest
were reported

Selective reporting (reporting bias)

Low risk

None reported.

Other bias

Low risk

None reported.

Characteristics of excluded studies
Kitabchi 1976
Reason for exclusion

comparison groups were IV and subcutaneous insulin versus IM insulin
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